# Inotropes {#sec-inotropes}

Inotropes are drugs that ↑ force and velocity of myocardial contraction, causing a primary ↑ SV and a secondary ↑ in CO and BP. Inotropes are divided based on their effect on SVR into:

* Standard inotropes\
Catecholamines (or derived), which act to ↑ cAMP.
* Inodilators\
Phosphodiesterase inhibitors. 

:::column-margin
Although we like to conceptually separate inotropes from @sec-vasopressors, there is substantial overlap in the pharmacodynamic activity of many drugs in either category.\
\
My preference for nomenclature is to use the umbrella term **vasoactive** for all agents used to manipulate haemodynamic parameters, and then categorise them based on their primary function:

* **Inotrope** for agents that ↑ the force of myocardial contraction
	* The subcategory **inodilator** for drugs which also ↓ SVR
* **Vasopressor** for agents that ↑ SVR
* **Vasodilator** for agents that ↓ SVR
:::

## Practice

* Goal is restoration of tissue perfusion\
Regular clinical assessment.
* Circulatory failure
* Invasive arterial monitoring

## Contraindications


## Comparison

: Comparison of Catecholamine Inotropes

+------------------+----------------------------------------+-----------------------------------+
| Drug             | Adrenaline                             | Dobutamine                        |
+==================+========================================+===================================+
| Overview         | Endogenous catecholamine               | Synthetic catecholamine           |
|                  |                                        |                                   |
|                  | * Mixed non-selective α and β activity | * Predominantly β~1~              |
|                  |                                        | * Nonspecific α effects at ↑ dose |
+------------------+----------------------------------------+-----------------------------------+
| Dosing           | 0-0.3µg/kg/min                         |                                   |
+------------------+----------------------------------------+-----------------------------------+
| Relative Actions | * ↑ Inotropy                           | * ↑ Inotropy                      |
|                  | * ↑ SVR                                | * ↓ SVR                           |
+------------------+----------------------------------------+-----------------------------------+
| Disadvantages    | * ↑ Myocardial O~2~ consumption        | * ↓ SVR\                          |
|                  | * Type B lactataemia                   | Hypotension.                      |
|                  | * Arrhythmogenic                       | * ↑ Myocardial O~2~ consumption   |
|                  |                                        | * Arrhythmogenic                  |
+------------------+----------------------------------------+-----------------------------------+


: Comparison of Inodilators

+------------------+----------------------------------+--------------------------------------------------------------------------------+
| Drug             | Milrinone                        | Levosimendan                                                                   |
+==================+==================================+================================================================================+
| Overview         |                                  | Calcium sensitiser that ↑ myocardial contraction with minimal ↑ in O~2~ demand |
|                  |                                  |                                                                                |
+------------------+----------------------------------+--------------------------------------------------------------------------------+
| Dosing           | 0-0.5µg/kg/min                   | 12.5mg over 24 hours                                                           |
+------------------+----------------------------------+--------------------------------------------------------------------------------+
| Relative Actions | * ↑ Inotropy                     | * ↑ Inotropy                                                                   |
|                  | * ↓ SVR                          | * ↓ SVR                                                                        |
|                  |                                  | * Long duration of action\                                                     |
|                  |                                  | Long half-life:                                                                |
|                  |                                  |     * Persistent improvement in myocardial performance                         |
|                  |                                  |     * Non-titrateable                                                          |
|                  |                                  |     * Persistent vasodilation which may require compensatory pressors          |
|                  |                                  |     * Can be re-dosed after ~1 week if desired                                 |
+------------------+----------------------------------+--------------------------------------------------------------------------------+
| Disadvantages    | * ↑ Arrhythmia                   | * ↓ SVR                                                                        |
|                  | * ↓ SVR                          | * Expensive                                                                    |
|                  | * Requires loading               |                                                                                |
|                  | * Longer t~1/2~ ↓ titrateability |                                                                                |
|                  | * Renally cleared                |                                                                                |
+------------------+----------------------------------+--------------------------------------------------------------------------------+


## Key Studies

**Cardiogenic Shock**:

{{< include /trials/doremi.qmd >}}


**Decompensated Heart Failure**:

{{< include /trials/lido.qmd >}}
* SURVIVE
* REVIVE


**Cardiac Surgery**:

{{< include /trials/levo_cts.qmd >}}
{{< include /trials/cheetah.qmd >}}


**Sepsis**:

{{< include /trials/leopards.qmd >}}


---

## References

1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.
1. Mathew R, Di Santo P, Jung RG, et al. [Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock](https://www.nejm.org/doi/full/10.1056/NEJMoa2026845). New England Journal of Medicine. 2021;385(6):516-525.
